Long‐term bisphosphonate therapy and atypical femoral fracture: Can you have too much of a good thing?-Reference-Cited by-同舟云学术

Long‐term bisphosphonate therapy and atypical femoral fracture: Can you have too much of a good thing?

Published:2021-11-04 Issue:12 Volume:87 Page:4877-4879
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Brit J Clinical Pharma

Author:

Walker Lauren E.¹^ORCID,Cooper Cyrus²

Affiliation:

1. The Wolfson Centre for Personalised Medicine School of Life Sciences, Biosciences Building, Crown Street, University of Liverpool Liverpool L69 7BE United Kingdom

2. MRC Lifecourse Epidemiology Unit University of Southampton

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bcp.15110

Reference24 articles.

1. Osteoporosis in the European Union: a compendium of country-specific reports

2. World-wide Projections for Hip Fracture

3. Predictive Value of BMD for Hip and Other Fractures

4. Body mass index as a predictor of fracture risk: A meta-analysis

5. A meta-analysis of previous fracture and subsequent fracture risk

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Towards understanding how bisphosphonate‐dependent alterations to nutrient canal integrity can contribute to risk for atypical femoral fractures: Biomechanical considerations and potential relationship to a real‐world analogy;BioEssays;2023-12-07

2. Fracture risk after deprescription of bisphosphonates: Application of real-world data in primary care;Atención Primaria;2023-07

3. Are secondary effects of bisphosphonates on the vascular system of bone contributing to increased risk for atypical femoral fractures in osteoporosis?;BioEssays;2023-02-20